A single dose of escitalopram blunts the neural response in the thalamus and caudate during monetary loss.

Adult Caudate Nucleus / cytology Escitalopram / administration & dosage Female Humans Magnetic Resonance Imaging Male Neurons / drug effects Punishment Reward Selective Serotonin Reuptake Inhibitors / administration & dosage Thalamus / cytology Young Adult

Journal

Journal of psychiatry & neuroscience : JPN
ISSN: 1488-2434
Titre abrégé: J Psychiatry Neurosci
Pays: Canada
ID NLM: 9107859

Informations de publication

Date de publication:
27 04 2021
Historique:
entrez: 27 4 2021
pubmed: 28 4 2021
medline: 27 1 2022
Statut: epublish

Résumé

Selective serotonin reuptake inhibitors (SSRIs) show acute effects on the neural processes associated with negative affective bias in healthy people and people with depression. However, whether and how SSRIs also affect reward and punishment processing on a similarly rapid time scale remains unclear. We investigated the effects of an acute and clinically relevant dose (20 mg) of the SSRI escitalopram on brain response during reward and punishment processing in 19 healthy participants. In a doubleblind, placebo-controlled study using functional MRI, participants performed a well-established monetary reward task at 3 time points: at baseline; after receiving placebo or escitalopram; and after receiving placebo or escitalopram following an 8-week washout period. Acute escitalopram administration reduced blood-oxygen-level-dependent (BOLD) response during punishment feedback in the right thalamus (family-wise error corrected [FWE] p = 0.013 at peak level) and the right caudate head (pFWE = 0.011 at peak level) compared to placebo. We did not detect any significant BOLD changes during reward feedback. We included only healthy participants, so interpretation of findings are limited to the healthy human brain and require future testing in patient populations. The paradigm we used was based on monetary stimuli, and results may not be generalizable to other forms of reward. Our findings extend theories of rapid SSRI action on the neural processing of rewarding and aversive stimuli and suggest a specific and acute effect of escitalopram in the punishment neurocircuitry.

Sections du résumé

Background
Selective serotonin reuptake inhibitors (SSRIs) show acute effects on the neural processes associated with negative affective bias in healthy people and people with depression. However, whether and how SSRIs also affect reward and punishment processing on a similarly rapid time scale remains unclear.
Methods
We investigated the effects of an acute and clinically relevant dose (20 mg) of the SSRI escitalopram on brain response during reward and punishment processing in 19 healthy participants. In a doubleblind, placebo-controlled study using functional MRI, participants performed a well-established monetary reward task at 3 time points: at baseline; after receiving placebo or escitalopram; and after receiving placebo or escitalopram following an 8-week washout period.
Results
Acute escitalopram administration reduced blood-oxygen-level-dependent (BOLD) response during punishment feedback in the right thalamus (family-wise error corrected [FWE] p = 0.013 at peak level) and the right caudate head (pFWE = 0.011 at peak level) compared to placebo. We did not detect any significant BOLD changes during reward feedback.
Limitations
We included only healthy participants, so interpretation of findings are limited to the healthy human brain and require future testing in patient populations. The paradigm we used was based on monetary stimuli, and results may not be generalizable to other forms of reward.
Conclusion
Our findings extend theories of rapid SSRI action on the neural processing of rewarding and aversive stimuli and suggest a specific and acute effect of escitalopram in the punishment neurocircuitry.

Identifiants

DOI: 10.1503/jpn.200121 PMID: 33904667 PMC: PMC8327975
pubmed: 33904667
doi: 10.1503/jpn.200121
pmc: PMC8327975
doi:

Substances chimiques

Serotonin Uptake Inhibitors 0
Escitalopram 4O4S742ANY

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

E319-E327

Informations de copyright

© 2021 CMA Joule Inc. or its licensors.

Déclaration de conflit d'intérêts

E. Forbes declares an honorarium for editorial activities for the Association for Psychological Science; paid consultancy for DSMB, Durham VA (sponsor), Otsuka (funder); an honorarium for mentoring activities as part of Research Centre, Brown University; research funding from the National Institutes of Health; and an honorarium for a grant review from the National Institutes of Health, all outside the published work. No other competing interests declared.

Références

Neuropsychopharmacology. 2010 May;35(6):1290-301
pubmed: 20107431
Biol Psychiatry. 2010 Jul 15;68(2):118-24
pubmed: 20303067
Neuropsychopharmacology. 2008 Aug;33(9):2291-9
pubmed: 17940553
Am J Psychiatry. 2009 Jun;166(6):702-10
pubmed: 19411368
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7900-5
pubmed: 27357684
PLoS One. 2014 May 07;9(5):e94640
pubmed: 24804780
Neuropsychopharmacology. 2018 Dec;43(13):2645-2651
pubmed: 30305705
Biol Psychiatry. 2010 Mar 1;67(5):439-45
pubmed: 20034615
Neuroscience. 2010 Apr 14;166(4):1023-35
pubmed: 20109531
Int Clin Psychopharmacol. 2009 May;24(3):119-25
pubmed: 19367152
Annu Rev Neurosci. 2015 Jul 8;38:1-23
pubmed: 25705929
Trends Cogn Sci. 2012 Jan;16(1):72-80
pubmed: 22177032
J Neurosci. 2009 Sep 23;29(38):11993-9
pubmed: 19776285
Cogn Affect Behav Neurosci. 2010 Mar;10(1):107-18
pubmed: 20233959
Curr Biol. 2014 Oct 6;24(19):2314-8
pubmed: 25242032
Psychopharmacology (Berl). 2009 Sep;205(4):667-77
pubmed: 19529923
Science. 2006 Feb 10;311(5762):861-3
pubmed: 16469930
Eur Neuropsychopharmacol. 2013 Aug;23(8):919-30
pubmed: 23051938
Drugs Today (Barc). 2004 Feb;40(2):121-31
pubmed: 15045034
Neuropsychopharmacology. 2018 May;43(6):1425-1435
pubmed: 29297512
Neuropsychopharmacology. 2003 Jan;28(1):148-52
pubmed: 12496951
Trends Neurosci. 1996 Sep;19(9):378-83
pubmed: 8873352
Am J Psychiatry. 2009 Oct;166(10):1178-84
pubmed: 19755572
Psychol Med. 1998 May;28(3):559-71
pubmed: 9626713
Am J Psychiatry. 2004 May;161(5):826-35
pubmed: 15121647
Neuropsychopharmacology. 2019 Mar;44(4):793-804
pubmed: 30420603
Depress Anxiety. 2014 Mar;31(3):233-49
pubmed: 24151118
Psychiatry Res. 2018 Feb;260:353-359
pubmed: 29232577
Brain. 2008 Aug;131(Pt 8):2084-93
pubmed: 18579575
Neuroimage. 2000 Jul;12(1):20-7
pubmed: 10875899
Mol Psychiatry. 2009 Nov;14(11):1040-50
pubmed: 18362913
Trends Cogn Sci. 2008 Jan;12(1):31-40
pubmed: 18069045
Neuroimage. 2010 Jan 15;49(2):1161-70
pubmed: 19833214
Am J Psychiatry. 2018 Nov 1;175(11):1111-1120
pubmed: 29921146
Neuropsychopharmacology. 2005 Dec;30(12):2205-15
pubmed: 15886717
Neuropsychopharmacology. 2005 Sep;30(9):1724-34
pubmed: 15827569
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Eur J Pharmacol. 2008 Feb 12;580(3):350-4
pubmed: 18177637
Neuropsychopharmacology. 2011 Jan;36(1):98-113
pubmed: 20736991
Psychopharmacology (Berl). 2006 Oct;188(3):263-72
pubmed: 16955282
Naunyn Schmiedebergs Arch Pharmacol. 1995 Jun;351(6):624-9
pubmed: 7675121
Neuropsychopharmacology. 2005 Jul;30(7):1269-77
pubmed: 15702136
Transl Psychiatry. 2016 Nov 22;6(11):e957
pubmed: 27874847
Psychiatry Res. 2004 Nov 30;129(1):21-7
pubmed: 15572181
Neuropsychopharmacology. 2016 Sep;41(10):2566-76
pubmed: 27125304
Am J Psychiatry. 2004 Jul;161(7):1256-63
pubmed: 15229059
Biol Psychiatry. 1998 Oct 1;44(7):526-33
pubmed: 9787876
Curr Biol. 2014 Sep 8;24(17):2033-40
pubmed: 25155504
Neuron. 2014 Mar 19;81(6):1360-1374
pubmed: 24656254
Compr Psychiatry. 2002 Jan-Feb;43(1):69-73
pubmed: 11788923
Biol Psychiatry. 2013 Jul 1;74(1):26-31
pubmed: 23374637
Cognition. 2015 Jun;139:154-67
pubmed: 25824862
Psychopharmacology (Berl). 2014 Feb;231(4):623-36
pubmed: 24337875
Philos Trans R Soc Lond B Biol Sci. 2013 Feb 25;368(1615):20120407
pubmed: 23440467
Am J Psychiatry. 2009 Jan;166(1):64-73
pubmed: 19047324
PLoS Comput Biol. 2008 Feb;4(2):e4
pubmed: 18248087
Front Integr Neurosci. 2013 Aug 27;7:60
pubmed: 23986662
Neuropsychopharmacology. 2005 Jun;30(6):1138-47
pubmed: 15689962
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Neuroimage. 2012 Feb 1;59(3):2142-54
pubmed: 22019881
Trends Cogn Sci. 2016 Jan;20(1):15-24
pubmed: 26545853
J Psychopharmacol. 1991 Jan;5(4):305-15
pubmed: 22282829
Br J Psychiatry. 2009 Aug;195(2):102-8
pubmed: 19648538
Psychiatry Clin Neurosci. 2011 Mar;65(2):191-8
pubmed: 21414093
Int Clin Psychopharmacol. 2002 Jun;17 Suppl 1:S1-12
pubmed: 12369606
J Clin Psychopharmacol. 1987 Dec;7(6 Suppl):24S-35S
pubmed: 3323264
Neuropsychopharmacology. 2002 Dec;27(6):949-59
pubmed: 12464452
Brain Res. 1992 Jul 3;584(1-2):322-4
pubmed: 1515949
J Neurosci. 2015 Feb 11;35(6):2717-30
pubmed: 25673861
Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2855-63
pubmed: 18456724
Neural Netw. 2002 Jun-Jul;15(4-6):603-16
pubmed: 12371515

Auteurs

Carolin A Lewis (CA)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Karsten Mueller (K)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Rachel G Zsido (RG)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Janis Reinelt (J)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Ralf Regenthal (R)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Hadas Okon-Singer (H)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Erika E Forbes (EE)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Arno Villringer (A)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Julia Sacher (J)

From the Emotion Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Lewis, Zsido, Sacher); the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity, Leipzig, Germany (Lewis, Zsido); the Department of Psychiatry and Psychotherapy, Medical School, University of Tuebingen, Germany (Lewis); the Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (Mueller, Reinelt, Villringer); the Max Planck School of Cognition, Leipzig, Germany (Zsido); the Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany (Regenthal); the Department of Psychology, School of Psychological Sciences, University of Haifa, Haifa, Israel (Okon-Singer); the Integrated Brain and Behavior Research Center (IBBR), University of Haifa, Haifa, Israel (Okon-Singer); the Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (Forbes); and the Clinic for Cognitive Neurology, University of Leipzig, Leipzig, Germany (Villringer, Sacher).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › A single dose of escitalopram blunts the...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Noyaux gris centraux › Corps strié › Néostriatum › Noyau caudé › A single dose of escitalopram blunts the...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzofuranes › Escitalopram › A single dose of escitalopram blunts the...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A single dose of escitalopram blunts the...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › A single dose of escitalopram blunts the...
questionsmedicales.fr › Cellules › Neurones › A single dose of escitalopram blunts the...
questionsmedicales.fr › Sciences sociales › Sociologie › Contrôle social informel › Punition › A single dose of escitalopram blunts the...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Renforcement (psychologie) › Récompense › A single dose of escitalopram blunts the...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents sérotoninergiques › Inhibiteurs sélectifs de la recapture de la sérotonine › A single dose of escitalopram blunts the...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Diencéphale › Thalamus › A single dose of escitalopram blunts the...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › A single dose of escitalopram blunts the...